个性化基因组编辑——角膜营养不良的未来
本文综述了CRISPR/Cas9基因编辑在角膜营养不良治疗中的应用前景。多数角膜营养不良为单基因、高外显率且遗传模式明确的疾病,结合角膜可及性、易观察性和免疫豁免特性,使其成为个性化基因组编辑的理想平台。脱靶切割和递送效率是当前主要关注点,CRISPR/Cas9已进入首批临床试验,基因编辑治疗角膜营养不良的潜力值得期待。
要点
- 多数角膜营养不良为单基因、高外显率且遗传模式明确的疾病,适合个性化基因组编辑。
- 角膜的可及性、易观察性和免疫豁免特性使基因编辑治疗具有吸引力。
- 脱靶切割是CRISPR/Cas9治疗的主要担忧,当前研究聚焦于提高全基因组特异性。
核心结论
- CRISPR/Cas9基因编辑技术的进步使个性化基因组编辑进入临床成为可能。
- 角膜营养不良因其遗传背景和角膜特性成为个性化基因组编辑的理想平台。
- CRISPR/Cas9已用于首批临床试验,基因编辑治疗角膜营养不良的潜力看起来很有希望。
研究设计与样本
- 本文为综述,讨论治疗性基因编辑在角膜营养不良中的现状。
主要发现
- Cas9介导的双链断裂(DSBs)可通过不同修复机制靶向多种致病突变。
- 多数角膜营养不良为单基因、高外显率且遗传模式明确的疾病。
- 脱靶切割是CRISPR/Cas9治疗应用的主要担忧,当前基因编辑领域致力于提高Cas9的全基因组特异性以最小化脱靶事件风险。
- 将CRISPR/Cas9递送至不同组织是关键焦点,正在探索多种病毒和非病毒平台以开发高效、特异且无毒的载体。
局限性
- 脱靶切割是CRISPR/Cas9治疗应用的主要担忧。
- 将CRISPR/Cas9递送至不同组织是关键焦点,仍需开发高效、特异且无毒的载体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The potential of personalised genome editing reaching the clinic has come to light due to advancements in the field of gene editing, namely the development of CRISPR/Cas9. The different mechanisms of repair used to resolve the double strand breaks (DSBs) mediated by Cas9 allow targeting of a wide range of disease causing mutations. Collectively, the corneal dystrophies offer an ideal platform for personalised genome editing; the majority of corneal dystrophies are monogenic, highly penetrant diseases with a known pattern of inheritance. This genetic background coupled with the accessibility, ease of visualisation and immune privilege status of the cornea make a gene editing strategy for the treatment of corneal dystrophies an attractive option. Off-target cleavage is a major concern for the therapeutic use of CRISPR/Cas9, thus current efforts in the gene editing field are focused on improving the genome-wide specificity of Cas9 to minimise the risk of off-target events. In addition, the delivery of CRISPR/Cas9 to different tissues is a key focus; various viral and non-viral platforms are being explored to develop a vehicle that is highly efficient, specific and non-toxic. The rapid pace and enthusiasm with which CRISPR/Cas9 has taken over biomedical research has ensured the personalised medicine revolution has been realised. CRISPR/Cas9 has recently been utilised in the first wave of clinical trials, and the potential for a genome editing therapy to treat corneal dystrophies looks promising. This review will discuss the current status of therapeutic gene editing in relation to the corneal dystrophies.
引用
- Moore CBT, Christie KA, Marshall J, et al. Personalised genome editing - The future for corneal dystrophies. Prog Retin Eye Res. 2018. PMID: 29378321. doi:10.1016/j.preteyeres.2018.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。